Synthesis, in vitro, and in vivo evaluation of phosphate ester derivatives of combretastatin A-4

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 9, 2003, Pages 1505-1508

  Hadimani, Mallinath B ^a   Hua, Jianyi ^b   Jonklaas, M Devan ^a   Kessler, Raymond J ^a   Sheng, Yezhou ^b   Olivares, Adrian ^a   Tanpure, Rajendra P ^a   Weiser, Aimee ^a   Zhang, Jianxing ^a   Edvardsen, Klaus ^b   Kane, Robert R ^a   Pinney, Kevin G ^a  

^a BAYLOR UNIVERSITY   (United States)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COMBRETASTATIN A4; ORGANOPHOSPHATE; PROTEIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD FLOW; CANCER TISSUE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG SCREENING; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN;

EID: 12444259666     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00206-3     Document Type: Article

References (20)

1. Siemann D.W. Int. J. Rad. Onc., Bio., Phys. 54:2002;1472.
2. Hori K., Saito S., Nihei Y., Suzuki M., Sato Y. Jpn. J. Cancer Res. 90:1990;1026 Blakey D.C., Ashton S.E., Westwood F.R., Walker M., Ryan A.J. Int. J. Rad. Onc., Bio., Phys. 54:2002;1497 Chaplin D.J., Hill S.A. Int. J. Rad. Onc., Bio., Phys. 54:2002;1491.
3. Hori K., Saito S., Nihei Y., Suzuki M., Sato Y. Jpn. J. Cancer Res. 90:1990;1026 Blakey D.C., Ashton S.E., Westwood F.R., Walker M., Ryan A.J. Int. J. Rad. Onc., Bio., Phys. 54:2002;1497 Chaplin D.J., Hill S.A. Int. J. Rad. Onc., Bio., Phys. 54:2002;1491.
4. Hori K., Saito S., Nihei Y., Suzuki M., Sato Y. Jpn. J. Cancer Res. 90:1990;1026 Blakey D.C., Ashton S.E., Westwood F.R., Walker M., Ryan A.J. Int. J. Rad. Onc., Bio., Phys. 54:2002;1497 Chaplin D.J., Hill S.A. Int. J. Rad. Onc., Bio., Phys. 54:2002;1491.
5. Tozer G.M., Prise V.E., Wilson J., Locke R.J., Vojnovic B., Statford M.R.L., Dennis M.F., Chaplin D.J. Cancer Res. 59:1999;1626 Eikesdal H.P., Bjerkvig R., Mella O., Dahl O. Radiotherapy and Oncology. 60:2001;147.
6. Tozer G.M., Prise V.E., Wilson J., Locke R.J., Vojnovic B., Statford M.R.L., Dennis M.F., Chaplin D.J. Cancer Res. 59:1999;1626 Eikesdal H.P., Bjerkvig R., Mella O., Dahl O. Radiotherapy and Oncology. 60:2001;147.
7. Kanthou C., Tozer G.M. Blood. 99:2002;2060 Tozer G.M., Prise V.E., Wilson J., Cemazar M., Shan S., Dewhirst M.W., Barber R., Vojnovic B., Chaplin D.J. Cancer Res. 61:2001;6413 Galbraith S.M., Chaplin D.J., Lee F., Stratford M.R.L., Locke R.J., Vojnovic B., Tozer G.M. Anticancer Res. 21:2001;93.
8. Kanthou C., Tozer G.M. Blood. 99:2002;2060 Tozer G.M., Prise V.E., Wilson J., Cemazar M., Shan S., Dewhirst M.W., Barber R., Vojnovic B., Chaplin D.J. Cancer Res. 61:2001;6413 Galbraith S.M., Chaplin D.J., Lee F., Stratford M.R.L., Locke R.J., Vojnovic B., Tozer G.M. Anticancer Res. 21:2001;93.
9. Kanthou C., Tozer G.M. Blood. 99:2002;2060 Tozer G.M., Prise V.E., Wilson J., Cemazar M., Shan S., Dewhirst M.W., Barber R., Vojnovic B., Chaplin D.J. Cancer Res. 61:2001;6413 Galbraith S.M., Chaplin D.J., Lee F., Stratford M.R.L., Locke R.J., Vojnovic B., Tozer G.M. Anticancer Res. 21:2001;93.
10. Pettit G.R., Singh S.B., Hamel E., Lin C.M., Alberts D.S., Garcia-Kendall D. Experientia. 45:1989;209.
11. Dowlatti A., Robertson K., Cooney M., Petros W.P., Stratford M., Jesberger J., Rafie N., Overmoyer B., Makkar V., Stambler B., Taylor A., Waas J., Lewin J.S., McCrae K.R., Remick S.C. Cancer Res. 62:2002;3408.
12. Pettit G.R., Singh S.B., Boyd M.R., Hamel E., Pettit R.K., Schmidt J.M., Hogan F. J. Med. Chem. 38:1995;1666.
13. Pettit G.R., Rhodes M.R. Anti-Cancer Drug Des. 13:1998;183.
14. 31P NMR, HPLC, HRMS). Supplemental material containing a detailed experimental procedure and full characterization details for each compound is available from the authors upon request.
15. Oligonucleotides and Analogues: A Practical Approach; Asseline, U.I., Ed.; IRL Press: Oxford, 1991.
16. Hansen M.B., Nielsen S.E., Berg K. J. Immunol. Meth. 119:1989;203.
17. 50 was defined as the drug concentration that reduced cell viability 50% in comparison with control.
18. Relative cytoxicities were examined in several cell lines in addition to the MHEC5-T endotheliaoma model (data not shown).
19. Unpublished data, M. L. Trawick, Baylor University.
20. 3 (a size without development of necrosis), mice received ip doses of either 10 mg/kg or 100 mg/kg of the various compounds. Twenty-four h later 0.25 mL of diluted FluoSphere beads (1:6 in physiological saline) was injected in the tail vein. The animals were sacrificed after 3 min and the tumor was removed. Cryosections (8 μm thick) were directly examined under a fluorescent microscope. Blood vessels were indicated by blue fluorescence from injected microbeads. For quantification, three sections from three tumors treated in each group were examined and in each section, more than 70% of the area was automatically recorded with a microscopic digital camera at ×100 magnification. The computer program Stage Pro (Media Cybernetics, MD) was used to control the picture recording. Image analysis was performed with Image Plus software (Media Cybernetics, MD). The results were expressed as vessel density decrease in percent of the control.